As a result of this, we analyzed alterations and survival in serous ovarian cancer and found that BDP1 homodeletions and decreased expression negatively impacted disease‐free progression in patients (p = 0.0271, q = 0.0542), Figure 1C. The gene discussed is BDP1; the disease is ovarian serous adenocarcinoma.